Skip to Main Content

Paper Details

Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
21
2022
Cancer, TP53, TP53 hotspot, TP53 mutations, TP53 variants, cancer, cancer cells, driver gene, hotspot mutations, hotspots, lung cancer, mutant p53, non, non-cancerous lesions, patient, patients, tumour, tumours
Author NameAffiliation
Chaitanya BandlamudiKravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Chaitanya BandlamudiMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
Sharon A SavageClinical Genetics Branch, National Cancer Institute, National Institutes of Health
Sharon A SavageClinical Genetics Branch, National Cancer Institute, National Institutes of Health
Arnold J LevineSimons Center for Systems Biology, Institute for Advanced Study
Benjamin D GreenbaumMemorial Sloan Kettering Cancer Center
Benjamin D GreenbaumWeill Cornell Medical College
  • 1 - 8

Datasets

Release 1.2